Summary. We prospectively investigated 27 patients with heparin-induced thrombocytopenia (HIT) type II who were subsequently treated with r-hirudin. Patients with venous or arterial thromboembolism were treated with activated partial thromboplastin time (aPTT)-controlled intravenous r-hirudin (n 19; mean 19´3 d) followed by subcutaneous r-hirudin (n 6; mean 22´5 d) and oral anticoagulation. Patients without thromboembolism were treated with subcutaneous r-hirudin (n 8; mean 25´9 d). Four patients were readmitted to subcutaneous r-hirudin for a mean duration of 32 d. The incidence of r-hirudin antibodies was 84% for intravenously treated patients and 50% in subcutaneously treated patients. The patients (n 27) showed a 74% overall incidence of r-hirudin antibodies, mainly of the IgG-subclass, without seroconversion before day 6 and after day 32 of r-hirudin treatment or during r-hirudin treatment. None of the patients showed onset or recurrence of venous or arterial thromboembolism, systemic allergic reactions or IgE-antibody development.
Naturally occurring hirudin is a polypeptide consisting of 65±66 aminoacids (Dodt et al, 1984) . It is produced in the salivary glands of the leech Hirudo medicinalis and is the most potent naturally occurring thrombin inhibitor known (Markwardt, 1994) . Recombinant (r)-hirudin differs from naturally occurring hirudin due to the lack of a sulphate group on tyrosine number 63 (CGP 39393) (Ma Èrki et al, 1991) or the translocation of the ®rst 2-N-terminal amino acids (Leu 1 and Tyr 2), three disulphide bonds and desulphated tyrosine 63 (HBW 023). The conjugation of r-hirudin and two molecules of polyethylenglycol 5000 (PEG-hirudin) was shown to increase its plasma half-life (Esslinger et al, 1997) . Hirudin reacts with thrombin, forming a 1:1 complex at the active site of thrombin to inhibit its proteolytic activity (Markwardt, 1994; Wallis, 1996) .
Preclinical (Markwardt et al, 1988) and clinical trials have shown that hirudin is an effective anticoagulant for the prevention of venous thromboembolism in patients undergoing elective hip surgery (Eriksson et al, 1996) , for patients with chronic stable coronary artery disease (Zoldhelyi et al, 1993) , acute myocardial infarction (Antman et al, 1996; GUSTO IIB investigators 1996) , unstable angina pectoris (Topol et al, 1994) , stable angina undergoing coronary angioplasty (Van den Bos et al, 1993) , in combination with intracoronary thrombolysis (Neuhaus et al, 1994) and for treatment of deep-vein thrombosis (Schiele et al, 1997) . The data reported so far indicate that r-hirudin shows low immunogenic properties despite its polypeptide nature and the great phylogenetic distance between Hirudo medicinalis and man.
R-hirudin is the currently accepted treatment for patients with heparin-induced thrombocytopenia (HIT) type II Harenberg et al, 1997) . HIT type II is related mainly to antibodies induced by the heparin platelet factor 4 complex (Amiral et al, 1995) , which interacts with platelets via the FcgRII receptor (Chong et al, 1989) , endothelial cells and leucocytes, causing thrombocytopenia and thromboembolic events (Cines et al, 1987) . However, the increased thrombotic risk persists for at least 30 d following the discontinuation of heparin (Warkentin, 1997) .
We have developed an ELISA method to detect the isotypes of anti-hirudin antibodies and used this to investigate the occurrence of anti-hirudin antibodies and their biological relevance in 27 HIT type II patients who had been long-term or recurrently treated with recombinant hirudin, during a prospective study conducted between March 1997 and June 1998.
PATIENTS AND METHODS

Patients.
Patients with clinically con®rmed diagnosis of HIT type II (heparin treatment, thrombocytopenia with a platelet drop of >50% of initial value, thromboembolic complications and/or con®rmed heparin/PF4-antibodies followed by normalization of platelet count after cessation of heparin) were treated with intravenous r-hirudin only or intravenous followed by subcutaneous r-hirudin or subcutaneous r-hirudin only. The study was carried out according to the principles of the Declaration of Helsinki and informed consent was obtained from all patients.
Patients with renal failure, hepatic diseases or hereditary thrombophilia and bleeding diatheses were excluded from the study as were those patients with life-threatening underlying disease.
Treatment. Recombinant hirudin (Lepirudin, Re¯udan Ò ) was supplied by Hoechst-Marion-Roussel, Bad Soden, Germany.
Patients with thromboembolic complications were initially treated with intravenous r-hirudin during the acute phase receiving a r-hirudin bolus injection (0´2 mg/kg) followed by continuous infusion (0´1 mg/kg/h). The r-hirudin dose was adjusted according to the aPTT with a target prolongation of 1´5±2´5 times normal values. After the acute phase of HIT type II, anticoagulation was switched to subcutaneous administration of recombinant hirudin (25 mg b.i.d.) because of delayed oral anticoagulation due to further diagnostic or surgical interventions. The subcutaneous regime was introduced by overlapping the ®rst subcutaneous injection with the intravenous r-hirudin over a 1 h period.
Patients with clinically and laboratory con®rmed HIT type II without thromboembolic complications were treated with subcutaneous hirudin (25 mg b.i.d.) from the onset.
Long-term oral anticoagulation with phenprocoumon was introduced in all patients as soon as possible. Hirudin therapy was terminated as soon as the INR was >2´5. Intermittent treatment with subcutaneous recombinant hirudin, due to cessation of oral anticoagulation in some patients because of surgical or diagnostic interventions, was introduced as soon as the International Normalized Ratio (INR) < 2´5. During subcutaneous r-hirudin therapy, activated thromboplastin time (aPTT) and ecarin clotting time (ECT) were measured weekly.
Laboratory assessment. During r-hirudin treatment, standard serum chemistry including creatinine levels and liver enzymes were measured weekly. In the same settings blood cell count, haemoglobin level, haematocrit, and the coagulation parameters aPTT, ECT (Nowak & Bucha, 1996) and INR were assessed in patients treated with subcutaneous r-hirudin. For assessment of haemostasis parameters, venous blood was collected in citrate (11 mmol/l ®nal concentration). Plasma coagulation parameters were obtained immediately after blood withdrawal by clean venepuncture. Clotting times were measured in duplicate on KC-10 coagulometers (Amelung, Lemgo, Germany). The aPTT (pathrombtin, Behringwerke AG, Marburg, Germany; according to the manufacturer's instructions; normal range, 25±35 s) and ECT (Knoll AG, Ludwigshafen, Germany; test performed as described by Nowak & Bucha, 1996 ; normal range < 55 s) were assessed every day throughout intravenous r-hirudin therapy. These tests were repeated in cases of dose adjustment due to an aPTT target prolongation of 1´5±2´5 times normal values, as internationally recommended for suf®cient anticoagulation. The aPTT and ECT ratios were calculated as the mean normal aPTT (30 s) and upper normal ECT (55 s) divided by the individual aPTT and ECT, respectively.
While the patients were treated with subcutaneous (s.c.) r-hirudin, aPTT and ECT were measured weekly. The aPTTratios were calculated as the mean normal aPTT (30 s) divided by the individual aPTT. Baseline values were measured prior to the s.c. r-hirudin injection. Peak aPTT values, were measured 2 h (1´5±2´5 h) after the s.c. r-hirudin injection as recommended by Schiele et al (1994) . The ECT ratios were calculated as the normal ECT (55 s) divided by the individual value.
Anti-hirudin antibody ELISA. Anti-hirudin antibodies were measured prior to the ®rst exposure to r-hirudin and weekly while the patients were on either subcutaneous or intravenous r-hirudin treatment. Serum samples were collected by a clean puncture of an antecubital vein and aliquoted after centrifugation at 1800 g for 10 min and then frozen at À808C until analysis. The hirudin antibody ELISA was prepared according to Kemeny (1991) . In brief, microtitre plates (Greiner, Frickenhausen, Germany) were coated with r-hirudin in 0´1 M carbonate buffer, pH 9´2, and incubated for 24 h at 48C. After blocking with 1% BSA and PBS for 1 h, wells were washed three times with PBS tween. Patient's serum, diluted 1:50 with PBS, was added and incubated for 1 h at 378C. After washing, detection of IgA, IgE, IgG or IgM antibodies was performed by adding peroxidase-labelled speci®c goat-antihuman IgA, IgE, IgG or IgM. Finally, substrate solution was added and the reaction was stopped with sulphuric acid. The bound immunoglobulins were photometrically detected at 450 nm (microtitreplate reader Dynatech 7000, Plochingen, Germany). All samples were run in triplicate. Hirudin-speci®c antibodies were calculated by raw data (A 450 nm ) minus negative control (A 450 nm ). The mean values of 36 control subjects (A 450 nm ) plus 5-fold standard deviations were set as the upper normal limit for each subclass of the r-hirudin antibodies (data not shown).
Statistical analysis. Calculation of the mean is speci®ed by mean 6standard deviation (SD). The Whitney-MannWilcoxon test for paired and unpaired data was used for testing signi®cance in quantitative data. Values of P < 0´05 were considered to be statistically signi®cant.
RESULTS
Patients
Details of the patients are given in patients were treated with intravenous r-hirudin infusion (mean 16´5 d) due to severe HIT type II and thromboembolic events, followed by oral anticoagulation. Eight patients were initially treated with subcutaneous r-hirudin. One patient treated by i.v. r-hirudin only suffered reversible renal insuf®ciency as demonstrated by a serum-creatinine peaklevel of 141´4 mmol/l. The patient did not show accumulation of r-hirudin plasma levels as demonstrated by aPTT and ECT levels (data not shown). The overall mean serumcreatinine level was 76 mmol/l (range 44´2±141´4 mmol/l). Four patients were readmitted to subcutaneous r-hirudin treatment for a mean duration of 31´5 d.
Anti-hirudin antibodies
The development of anti-hirudin antibodies of the IgA, IgM and IgG subclass is given in Table II . None of the patients showed an antibody production prior to ®rst exposure to r-hirudin or before the sixth day of treatment. After the intravenous course of r-hirudin, 11/13 (84´6%) patients developed r-hirudin antibodies, mainly between the 10th and 30th day, without further seroconversion after the 32nd day. Patients treated with intravenous r-hirudin followed by subcutaneous r-hirudin developed r-hirudin antibodies in 5/6 (83%) cases (Table II) . When r-hirudin was administered subcutaneously, 4/8 (50%) of all patients developed antibodies mainly between the 10th and 30th day. The overall cumulative incidence of r-hirudin antibodies after 30 d in intravenously, subcutaneously, or intravenously followed by subcutaneously treated patients was 20/27 (74´1%). The patients developed antibodies mainly of the IgG subclass. Patients who were re-exposed to subcutaneous r-hirudin (n 4, mean 32 d) did not show seroconversion during treatment. No patient developed antihirudin antibodies of the IgE subclass or allergic reactions (¯ush, tachycardia, tachypnoea, erythema).
Coagulation parameters
The coagulation parameters aPTT and ECT for all of the patients are demonstrated in Figs 2±4 . Fig 2 shows the coagulation parameters and r-hirudin dose of 19 patients receiving intravenous r-hirudin. During the intravenous course of r-hirudin, 16/19 patients developed anti-r-hirudin antibodies. Coagulation parameters of 10 antibody-positive and nine antibody-negative patients (including six patients who developed anti-r-hirudin antibodies during the last 5 d of intravenous r-hirudin treatment)
were available for further analysis to evaluate the biological relevance of anti-r-hirudin antibodies. The mean aPTT and ECT ratios and the mean intravenous r-hirudin dosage of the ®rst and the last week of intravenous r-hirudin treatment is given in Fig 2. Fig 2A shows a signi®cant increase of the mean aPTT ratio (®rst week versus last week; 1´94 v 2´56) in the anti-r-hirudin antibody-positive patients (P < 0´01). When compared with the antibody-negative patients, the increase of the aPTT ratio was signi®cant (1´94±2´56 v 2´32±2´27; P < 0´05). Fig 2B demonstrates the ECT time course of the antibody-positive and antibody-negative patients. The ECT ratio showed a signi®cant increase in the antibody-positive patients (3´2 v 4´3; P < 0´05). However, the difference between antibody positive and negative patients was not signi®cant (P < 0´1; 3´2±4´3 v 4´1±3´8). As demonstrated in Fig 2C, the dose of intravenous r-hirudin did not signi®cantly differ between the antibody positive and negative population (0´09±0´09 mg/kg h v 0´09±0´08 mg/kg h). patients (n 14). Coagulation parameters of eight antibodypositive (including four patients who were initially treated with intravenous r-hirudin) and of six antibody-negative (including two patients who developed anti-r-hirudin antibodies during the last 5 d of subcutaneous r-hirudin treatment) were available for further analysis to evaluate the biological relevance of anti-r-hirudin antibodies. Fig 3A  demonstrates the signi®cant increase of the aPTT ratios in the antibody-positive patients (1´5 v 2´1; P < 0´05). Compared to antibody-negative patients the increase of the peak aPTT ratios remained signi®cant (1´5±2´1 v 2´3±2´1; P < 0´05). As shown in Fig 3B, the ECT ratio was signi®cantly increased in the antibody-positive population (2´4 v 2´7; P < 0´05) compared with the antibody-negative patients (2´4±2´7 v 1´9±2; P < 0´05).
Fig 4 depicts the baseline (prior to each s.c. r-hirudin application) aPTT and ECT-ratios of antibody-positive (n 8) and antibody-negative (n 6) patients. The baseline aPTT ratios (Fig 4A) showed a signi®cant increase in the antibodypositive population (1´1 v 1´6; P < 0´01) compared to antibody-negative patients (1´1±1´6 v 1´2±1´4; P < 0´05). The baseline ECT ratios (Fig 4B) showed an increase in the antibody-positive population which was not signi®cant when compared to antibody-negative patients (1´3±1´4; P > 0´05).
DISCUSSION
The present study was conducted to determine IgG, IgA, IgE and IgM antibody development and its biological relevance in HIT type II patients during long-term treatment with r-hirudin. The diagnosis of HIT type II was made according to accepted criteria (Wang et al, 1998) . We examined 27 patients treated with either intravenous, intravenous followed by subcutaneous, or subcutaneous r-hirudin. Four patients were re-exposed to subcutaneous r-hirudin. Patients suffering from HIT type II with arterial and/or venous thromboembolism were treated with intravenous r-hirudin as previously recommended . Based on the results from studies preventing deep vein thrombosis after elective hip surgery (Eriksson et al, 1996) and previously published data of subcutaneous r-hirudin application in patients with a venous thromboembolism (Schiele Table II . Incidence of r-hirudin antibodies of the IgG, IgM, IgA and IgE subclass is given as a percentage for patients treated by intravenous (i.v.), subcutaneous (s.c.), and intravenous followed by subcutaneous (i.v./s.c.) r-hirudin. Hirudin-speci®c antibodies were calculated by raw data (A 450 nm ) minus negative control (A 450 nm ). The mean values of 36 control subjects (A 450 nm ) plus 5 times standard deviations were set as the upper normal limit for each subclass of the r-hirudin antibodies (data not shown). 1997; Parent et al, 1993) , patients without thrombosis were treated with 25 mg b.i.d. r-hirudin injected into the abdominal wall. We found an overall incidence of r-hirudin IgG, IgA or IgM antibodies of 74´1% after r-hirudin treatment. However, we did not ®nd antibodies of the IgE-subclass. The patients developed mainly antibodies of the IgG-subclass. Our data partly support the study of 82 patients with HIT type II treated with r-hirudin (Eichler & Greinacher, 1996; Eichler et al, 1997 ) although we found a higher incidence of r-hirudin antibodies. This is most probably related to the longer treatment period in our study. By a sandwich ELISA anti-r-hirudin IgG antibodies were identi®ed in 38/82 (46´3%) (Eichler & Greinacher, 1996; Eichler et al, 1997) .
In an assigned subpopulation IgE antibodies directed against r-hirudin were also not found (Eichler & Greinacher, 1996; Eichler et al, 1997) . All patients were intravenously treated and antibodies of the IgA and IgM-subclass were not investigated.
The data published so far on r-hirudin treatment indicated low immunogenicity. Patients treated with r-hirudin in acute myocardial infarction as adjunctive therapy for thrombolysis (Antman et al, 1996; GUSTO IIb investigators 1996) , in unstable (Topol et al, 1994) and stable angina with (Van den Bos et al, 1993) and without (Zoldhelyi et al, 1993) coronary angioplasty and for prevention of deep-vein thrombosis after total hip replacement (Eriksson et al, 1996) or treatment of deep vein thrombosis (Schiele et al, 1997) , did not develop immunoallergic reactions or r-hirudin antibodies. But these regimens had not exceeded 5 d of treatment with r-hirudin when antibodies were investigated. Close et al (1994) reported allergic reactions in 3/200 volunteers and a positive skin test without systemic allergic reactions in three others after a second course of r-hirudin (CGP 39393). Another asymptomatic volunteer developed IgG and IgE r-hirudin antibodies. Five volunteers received a third course of s.c. r-hirudin and one developed a positive skin test.
The effect of r-hirudin-binding properties of the antibodies was previously reported in animal studies by decreasing renal r-hirudin elimination (Gygax et al, 1996) . In a 3-month i.v. tolerability study in dogs r-hirudin plasma kinetics demonstrated an accumulation of r-hirudin in the antibodypositive dogs in comparison with data from single-dose kinetics. They concluded that r-hirudin antibodies extend the r-hirudin plasma half-life without inhibiting the pharmacological activity (Gygax et al, 1996) . It is noteworthy that a dose reduction became necessary despite unaltered normal renal function. These data may explain the results in our patients as r-hirudin antibodies may in¯uence the metabolism of r-hirudin as demonstrated by our dose±response data in intravenously treated patients. At a constant intravenous r-hirudin dose the aPTT (P < 0´01) and ECT (P < 0´05) showed a signi®cant increase in antibody-positive patients compared to patients who did not develop r-hirudin antibodies. In the long-term subcutaneous application of r-hirudin the baseline and peak aPTT-values showed signi®cant prolongation in antibody-positive patients (P < 0´05). However, the ECT values showed a prolongation in antibody-positive patients compared to antibody-negative patients of lower signi®cance (P < 0´5).
On the other hand, thrombin plasma levels have been shown to be elevated during acute haemostasis and decreased during heparinization as demonstrated by thrombin±antith-rombin III levels in patients suffering venous thromboembolism . Thus, decreasing r-hirudin doses might be necessary for thrombin neutralization during followup treatment with r-hirudin after ®brotic organization, paci®cation or resolution of the thrombotic material, as reported for heparin treatment (Harenberg, 1992) . Increasing aPTT and ECT values may result. Compared to antibodynegative patients we showed a signi®cant increase of the aPTT and ECT in the antibody-positive population, indicating a reduced r-hirudin metabolism.
Although animal studies revealed possible antibody production directed to the N-terminal, C-terminal and thrombin-connecting domain of r-hirudin with r-hirudinneutralizing properties (Schlaeppi et al, 1990; Schlaeppi, 1991) , we presume that the r-hirudin neutralizing effects of the antibodies produced play a minor role, if any. This is in agreement with ®ndings of Verstraete et al (1993) and others (Markwardt et al, 1988; Bichler et al, 1988) . Based on our data, daily aPTT measurements are recommended when patients are intravenously treated long-term by r-hirudin for dose reduction. The aPTT and ECT values should be measured frequently in patients treated with subcutaneous r-hirudin for >6 d to reveal possible r-hirudin accumulation despite normal renal function, to prevent bleeding complications.
